Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation
- Chunxia Qiao†1,
- Meiyun Hu†1, 2,
- Leiming Guo†1,
- Ming Lv1,
- Zhou Lin1,
- Jing Geng1,
- Xiaoling Lang1,
- Xinying Li1,
- Yan Li1,
- Yuanfang Ma2,
- Jiannan Feng1Email author and
- Beifen Shen1Email author
© Qiao et al.; licensee BioMed Central Ltd. 2012
Received: 29 March 2012
Accepted: 26 June 2012
Published: 12 July 2012
As a member of the TNF superfamily, TRAIL could induce human tumor cell apoptosis through its cognate death receptors DR4 or DR5, which can induce formation of the death inducing signaling complex (DISC) and activation of the membrane proximal caspases (caspase-8 or caspase-10) and mitochondrial pathway. Some monoclonal antibodies against DR4 or DR5 have been reported to have anti-tumor activity.
In this study, we reported a novel mouse anti-human DR5 monoclonal antibody, named as LaDR5, which could compete with TRAIL to bind DR5 and induce the apoptosis of Jurkat cells in the absence of second cross-linking in vitro. Using computer-guided molecular modeling method, the 3-D structure of LaDR5 Fv fragment was constructed. According to the crystal structure of DR5, the 3-D complex structure of DR5 and LaDR5 was modeled using molecular docking method. Based on distance geometry method and intermolecular hydrogen bonding analysis, the key functional domain in DR5 was predicted and the DR5 mutants were designed. And then, three mutants of DR5 was expressed in prokaryotic system and purified by affinity chromatograph to determine the epitope of DR5 identified by LaDR5, which was consistent with the theoretical results of computer-aided analysis.
Our results demonstrated the specific epitope located in DR5 that plays a crucial role in antibody binding and even antineoplastic bioactivity. Meanwhile, revealed structural features of DR5 may be important to design or screen novel drugs agonist DR5.
KeywordsTRAIL Death receptor 5 Monoclonal antibody Apoptosis Breast cancer
TRAIL (tumor necrosis factor (TNF)-related apoptosis-inducing ligand) is a member of the TNF superfamily with the ability to induce apoptosis of tumor cells. At least five receptors for TRAIL have been identified. DR4 (TRAIL-R1)  and DR5 (TRAIL-R2) [2–4] are apoptosis-inducing receptors. They contain an intracellular death domain each. Upon receptor activation, DR4 and DR5 recruit FAS associated protein with death domain (FADD) [5–7] and caspase-8 to form the death-inducing signaling complex (DISC), which activates caspase-8, subsequently leading to the activation of executioner caspases such as caspase-3 that induce apoptosis [5, 8–10]. In addition, other signaling pathways leading to NF-kB activation and activation of the ERK, JNK, and p38 MAP kinase pathways are generated by a second complex that forms after the receptor-containing DISC ; DcR1 [2, 3, 11] and DcR2 [12, 13] are nonsignaling decoy receptors, which can bind to TRAIL but cannot trigger apoptosis. DcR1 lacks cytoplasmic death domain entirely , whereas DcR2 has a nonfunctional truncated death domain [3, 15]. DcR1 and DcR2 are unable to recruit FADD or signal apoptosis and inhibit apoptosis by sequestering TRAIL or by forming complexes with DR4 and DR5 to create heteromeric receptor complexes that are unable to activate signaling [16, 17]; Another receptor, osteoprotegerin, is a soluble receptor that binds to TRAIL with a dissociation constant of 400 nM, which is the lowest affinity of the known TRAIL receptors . It may have a more prominent role in bone and myeloid cell development than in regulating TRAIL-induced apoptosis.
A TRAIL monomer contains two anti-parallel beta-pleated sheets that form a beta-sandwich as a core scaffold and interacts with the adjacent subunits in a head-to-tail fashion to form a bell-shaped homo-trimmer. TRAIL and sDR5 form a tight 3:3 complex. Three sDR5 molecules in a curved shape bind to the three identical grooves between neighboring subunits of TRAIL, thereby inducing oligomerization of intracellular death domains. In complex TRAIL, residues 130–160 display the most remarkable structural changes. The conformation of residues 146–160 interact with the core scaffold and the residues 130–145 undergoes a drastic positional change. They penetrate into the receptor-binding site and interact with sDR5. This translocation is manifested by the strong electron densities observed for residues 130–135 of all the six TRAIL molecules in the asymmetric unit. Residues 131–135 penetrate into the central binding interface upon complex formation. The guanidino group of Arg132 makes a polar interaction with Tyr50 of sDR5. Asn134 and Thr135 interact with Glu70 and Asn81 of sDR5, respectively. The TRAIL mutant with residues 132–135 deletion showed a profound decrease in the binding affinity for sDR5 and cytotoxic activity in vitro using human hepatoma cells, suggesting those residues bear direct correlation with the activity of TRAIL .
TRAIL [20–22] and agonistic antibodies that recognize TRAIL receptors [23, 24] preferentially kill tumor cells and produce potent anti-tumor activity in a variety of experimental models. It is therefore hoped that these agents may be useful to treat cancer [9, 25–28]. Several clinical trials are ongoing with different TRAIL receptor agonists alone or in combination with other anti-cancer drugs. rTRAIL (soluble recombinant TRAIL), apoptosis-inducing anti-DR5/DR4 antibodies, or an agent that increases endogenous TRAIL expression are available strategies for cancer therapy [22, 24, 29]. Consistently, administration of TRAIL to mice bearing human tumors actively suppressed tumor progression  and improved survival of the animal. Furthermore, repeated intravenous injections of TRAIL in nonhuman primates did not cause detectable toxicity to normal tissues and organs, including liver tissues . However, susceptibility of human normal hepatocytes to TRAIL was reported recently , therefore agonists against DR4 or DR5 (e.g. anti-DR5 antibody) by activating apoptosis signal are becoming dramatically meaningful as candidate drugs for cancer therapy.
Recently, preclinical studies of TRAIL Receptor agonists indicate that they may be efficacious in a wide range of tumor types, especially when combined with chemotherapeutic agents. Receptor agonists, including recombinant forms of TRAIL and monoclonal antibodies against DR4 or DR5, are currently being evaluated in Phase II clinical trials in several cancer indications, in which at least four human or humanized monoclonal antibodies that target DR5 have been undergoing evaluation in clinical trials: Lexatumumab (HGS-ETR2), Apomab, Conatumumab (AMG 655), Tigatuzumab (CS1008). Most of them could activates intracellular caspases and induce apoptosis in a wide spectrum of human cancer cell lines in vitro and have anti-tumor activity in a dose-dependent manner as a single agent in xenograft models. They also have synergistic or additive activity in combination with chemotherapeutic agents or radiation in vitro and/or in vivo. Results of a Phase I single-agent study showed that anti-DR5 antibodies were well tolerated, and some of them were studied about the safety and efficacy in a Phase II study of patients with cancer .
Many DR5 agonist antibodies require additional cross-linking to achieve optimal activity in vitro, such as Apomab and Tigatuzumab (CS1008) [32–34]. In xenograft models, this cross-linking function is likely provided by binding to FcγRs . X-ray crystallographic analysis of Apomab-DR5 complex revealed an interaction epitope that partially overlaps with TRAIL binding regions. Apomab-DR5 interface is centered in a nearly continuous region of DR5, comprising residues 62–90, with additional contributions from residues 99–105, in which residues Arg65, Ser68 and Lys102 in DR5 seem to be the key sites. In contrast to Apomab, another phage-derived DR5 antibody (BDF1), which has little or no agonistic activity, interacts TRAIL with different epitope .
Computational approaches can provide relevant information to predict binding activity and key functional domains between antigen and antibody complex. It enables researchers to study interactions in atomic detail, and find out how a specific mutation affects its function. Computer-guided models combined with biological experiments could promote the process of identifying the key epitope for certain antigen in binding with its functional antibody. In this study, a novel anti-DR5 monoclonal antibody (mAb, IgG isotype), LaDR5, was screened from DR5-immunized mice, which was more suitable for genetic engineering contrasting to previous mAb (IgM isotype) . The potential anti-tumor activity of LaDR5 without cross-linking was characterized in vitro using Jurkat cells. With the major advances in computer processing, the 3-D structure of LaDR5 Fv fragment was simulated based on homology modeling method, and the antigen-antibody (i.e. DR5-LaDR5) complex model were generated using molecular docking method. As the key domain in DR5 being predicted, three mutants of DR5, DR5M1 (residues 35–36 were replaced by alanine), DR5M2 (residues 59, 62, 67–68 were replaced by alanine) and DR5M3 (residues 96, 98, 101 and 104 were replaced by alanine) were designed and prepared by affinity chromatograph, with which the differences of the functional epitope between TRAIL and LaDR5 were investigated.
Immunization, screening, purification and antigen binding of LaDR5
Immunization, screening and purification of LaDR5 were carried out using standard protocols described above. Some positive monoclonal antibody clones against DR5 were screened out by enzyme-linked immunosorbent assay (ELISA), in which LaDR5, an IgG1 subtype antibody identified by double immunodiffusion method, was screened out. Hybridoma cells were injected into the peritoneal cavity of BALB/c mice. After 14 days ascites were collected and purified LaDR5 was prepared by a column of protein A-Sepharose 4B.
Flow cytometry analysis of the positive cells treated with LaDR5 (10 μg/mL) in different tumor cell lines
standard DR5-mAb (%)
Cytotoxic and apoptotic activity of LaDR5
To test the cytotoxic activity of LaDR5 in vitro, Jurkat, U937, K562 and Daudi cell lines were cultured with diluted LaDR5. After 24 hours, cell viability was determined by MTT method. As shown in Figure 1D, only Jurkat cells died obviously in a dose-dependent manner (the survival ratio of Jurkat cells could decrease to 46 % when incubated with 10 μg/mL LaDR5, and the IC50 value was about 1 μg/mL). Meanwhile, although Daudi was also membrane-DR5 positive cell line, Jurkat was more sensitive.
Then we analyzed the apoptotic-inducing ability of LaDR5 to form a DR5-associated DISC in cell lysates, indicating that binding of LaDR5 to DR5 results in receptor oligomerization and initiation of apoptosis through the recruitment of FADD; meanwhile, only in Jurkat cells caspase-8 could be detected within 60 minutes (Figure 2B), indicating that LaDR5 was an effective agonist to trigger apoptotic response in Jurkat cells through FADD-caspase-8 pathway, while in LaDR5 insensitive cell line Daudi, the pathway was not triggered. Normal cells, isotype IgG treated cells and DR5-binding Antibody 366EC (with no apoptosis-inducing activity) were set as negative controls.
The 3-D modeling structures of LaDR5 Fv fragment and DR5-LaDR5 complex
To probe the mechanism of specific binding and investigate which domain was the most important epitope, the 3-D complex structure of LaDR5 Fv fragment and DR5 was constructed using Docking method and optimized with molecular mechanism and dynamics methods. The stable complex conformation was shown in Figure 3B, and the intact surface between DR5-LaDR5 was shown in Figure 3C, indicating the key residues of DR5: Ser35, Glu36, Phe59, Arg62, Arg65, Asp67, Ser68, Ser96, Glu98, Arg101, Lys102, Arg104 and Thr105.
Epitope Determination of LaDR5
Relative affinity constant (Kd) of LaDR5 to bind DR5s using ELISA method
Relative Affinity Constant of LaDR5 (nmol/L)
DR4 and DR5 are capable of transducing an apoptosis signal. Activation of DR4 or/and DR5 in various cancer cells triggers programmed cell death through the extrinsic pathway. Agents that activate DR4 or DR5, including TRAIL, have attracted substantial attention and investment as potential anti-cancer therapies. For TRAIL has no cytotoxicity in many normal cell types except for human liver cells , other agonistic reagents against the pro-apoptotic molecules DR4 or DR5, such as anti-DR5 mAbs, became an attractive anti-cancer strategy because of their potential for inducing tumor-specific cell death. Human or humanized anti-DR5 mAbs Lexatumumab (HGS-ETR2), Apomab, Conatumumab (AMG 655) and Tigatuzumab (CS1008) have been identified functional as a single agent or in combination with chemotherapy or other agents. Epitope of Apomab resides in residues 62–90 and residues 99–105 of DR5, which partially overlaps with that of TRAIL binding sites. DR5 residues Arg65, Ser68 and Lys102 seem to be most functional residues, while the nonfunctional anti-DR5 antibody BDF1 interacts different epitope from Apomab .
Computational approaches and protein structural analysis can provide relevant information about the functional roles of the epitope residues. Fast protocols using knowledge-based approaches and distance geometry analysis for predicting binding activity and key functional domains have been established. The physical interactions between antigen and antibody in their complex structures provide crucial insights into antigen function. It is precisely these structures that enable researchers to study interactions in atomic detail, and find out, for example, how a specific mutation in antigen affects its function, or how functional domain formed pharmacophore. Here computer-guided models were combined with biological experiments for the efficient determination and identification of the key domain for antigen (i.e. DR5) in binding with its functional antibody.
Thus, in this study, a functional anti-DR5 mAb, LaDR5, was screened out. The apoptosis-inducing and potential anti-tumor activity of LaDR5 without cross-linking was characterized in vitro. As shown in Figure 1, only membrane DR5-positive cell line Jurkat died with LaDR5 obviously in a dose-dependent manner, while DR5-low expression cell line K562, high expression cell line Daudi and U937 were insensitive to LaDR5. Furthermore, Jurkat cells displayed apoptosis feature when LaDR5 was added (Figure 2A). The DR5-associated DISC was investigated by western blot and immunoprecipitation in LaDR5-treated Jurkat or Daudi cell lysates, by which LaDR5 could induce the recruitment of FADD and then caspase-8 activation only in Jurkat cells (Figure 2B), which was consistent with the cytotoxic and apoptotic results. In Daudi cells, FADD-caspase-8 signal pathway was not triggered, the reason might be the failure of surface DR5 crosslinking by LaDR5 to form DISC or the interference of negative regulating molecules against caspase-8 activation (e.g. c-FLIP) .
Based on the computational methods and protein structural analysis, the key epitope of LaDR5 was predicted. First, the 3-D modeling structures of LaDR5 VH and VL were obtained, followed by constructing the 3-D structure of LaDR5 Fv fragment (Figure 3A). Then using Docking method, the 3-D complex structure of LaDR5 Fv fragment and DR5 (LaDR5-DR5) was constructed and optimized (Figure 3B); meanwhile, the key residues of DR5 identified by LaDR5 was determined theoretically (Figure 3C), according to which three DR5 mutants were designed and purified to confirm the prediction. The TRAIL or LaDR5 binding capacity order of DR5WT and DR5 mutants seemed to be DR5M1 > DR5WT > DR5M3 > DR5M2, suggesting that residues 59/62/67/68 (DR5M2) and 96/98/101/104 (DR5M3) in DR5 were key residues to bind TRAIL or LaDR5 (Figure 4B and Table 2). Furthermore, residues 59/62/67/68 (DR5M2) were more important in LaDR5 reaction, which were consistent with theoretical results predicted by computer-aided analysis. Furthermore, only DR5M1 as well as DR5WT could obviously interfere the cytotoxicity of LaDR5 in Jurkat cells, indicating residues 59/62/67/68 (DR5M2) or 96/98/101/104 (DR5M3) were predominant functional sites in the cytotoxic activity of LaDR5 (Figure 5A) as well as in the binding of LaDR5. Indeed the design procedure of DR5M1 was similar as that of the other mutants. The domain (i.e. Ser35, Glu36) of DR5 was the boundary of the binding sites, when the residues mutated in DR5M1 were replaced with alanine, the hydrophilic property of the domain was lost and the hydrophobic area was increased, then the change benefited to the binding affinity.
However, to our surprise, none of DR5s could inhibit the cytotoxicity of TRAIL (Figure 5B), with the possible reasons we conferred could be as follows: firstly, TRAIL identifies wider binding area of DR5 with higher affinity and/or triggers too strong cytotoxic signal to be interfered; secondly, no matter whether TRAIL dissociates or falls off after binding to membrane DR5, when TRAIL starts to bind, the downstream signals are induced immediately resulting in TRAIL-inducing cytotoxicity, although this statement should be supported by further experiments; thirdly, although the binding sites of DR5 identified by TRAIL known from the X-ray crystallographic analysis was overlapped by LaDR5 binding sites, the cytotoxic processes induced by TRAIL should be more than DR5-inducing pathway, for example, TRAIL can trigger cell death through DR4 rather than DR5, therefore in TRAIL-DR4 inducing cytotoxicity, it was difficult to inhibit downstream apoptosis signals by single DR5 analogs, which were more conceivable in our consideration.
Our work demonstrated the specific epitope located in DR5 that plays a crucial role in antibody binding; furthermore, revealed structural features of LaDR5-DR5 complex may be beneficial to design or screen novel antineoplastic drugs aganist DR5.
Fluorescein isothiocyanate (FITC) or HRP labeled goat anti-mouse antibody was purchased from Sigma-Aldrich; Mouse anti-caspase-8 monoclonal antibody (mAb) was from BD Bioscience; Mouse anti-DR5 monoclonal antibody was from eBioscience; Rabbit anti-FADD mAb was from Upstate; HRP conjugated anti-6 × His antibody (anti-His_HRP) was purchased from Abcam; Human T lymphocyte cell line Jurkat (ATCC No. TIB-152), chronic myelogenous leukemia K562 (ATCC No. CCL-243), human B lymphoblast Daudi (ATCC No. CCL-213), histiocytic lymphoma U937 (ATCC No. CRL-1593.2) and E.coli BL21 were stored in our laboratory.
Production and purification of mAb
Immunization and production of mAbs were carried out using standard protocols. In short, five 4-week-old female BALB/c mice were immunized subcutaneously with 100 μg of purified DR5 in complete Freund’s adjuvant per animal. Then animals were boosted twice at 4-week intervals with 100 μg of antigen in incomplete Freund’s adjuvant. Three days after the final injection, one mouse was sacrificed and its splenocytes were fused with NS-1 at a 6:1 ratio to a final concentration of 2 × 106 cell/mL, and 200μL cells was plated in each well of five 96-well plates. Hybrids were selected in RPMI1640 Medium supplemented with 20% fetal calf serum and 5 × 10-3 M hypoxanthine, 2 × 10-5 M aminopterin, and 8 × 10-4 M thymidine (HAT). After about 10 days, cell clones secreting antibodies against E34 were screened by ELISA, and the positive clones were selected and subcloned to establish stable cell lines.
5 × 106 hybridoma cells were injected into peritoneal cavity of BALB/c mice treated with paraffin in advance. After about twelve days, ascites were withdrawn and centrifuged at 1500 rpm for 5 minutes at 4°C. The supernatant was then applied to a column of protein A-Sepharose 4B. Specific-binding antibody was eluted with pH 4.0 citric acid buffer and dialyzed against PBS overnight.
We observed animal ethics during the research by complying with 3R principles (Replacement, Reduction and Refinement), such as usage of SPF-level mice, mice anesthetization, less animal number and mercy killing, etc. And the ethical approval granted for the study was given by the Ethics Committee of Basic Medical Sciences (Immunology).
ELISA plates (Nunc, Roskilde, Denmark) were coated with 5 μg/mL of DR4, DR5WT or its mutants at 4°C overnight and blocked with 3% BSA. 100μL diluted LaDR5 or TRAIL was added, followed by 100μL HRP_conjugated anti-mouse polyclonal antibody for 45 minutes at room temperature (RT for short, the same below). The peroxidase reaction was developed with color development solution. The light absorbance was measured with an ELISA reader.
Relative affinity constant of LaDR5 and TRAIL to bind DR5s determined by ELISA 
Here, in certain condition of diluted antigen, a0 means the antigen concentration; A is the absorbance value in this specific condition; A0 means the absorbance value of positive control with no antigen in the pre-incubated complex. The mean value of all Kd values was the final affinity constant.
DR4 or DR5 were resolved by 12% SDS-PAGE and then transferred to a nitrocellulose membrane. After blocking with 5 % milk in PBS at RT for 1 hour, the blots were probed with 5 μg/mL LaDR5 followed by horseradish peroxidase (HRP)-conjugated goat anti-mouse polyclonal antibody and developed by chemiluminescence.
Flow cytometry analysis
Cells (5 × 105) were collected by centrifugation and incubated with 5 μg/ml of LaDR5 or standard anti-DR5 antibody. Mouse IgG1 was set as negative control. Then cells were incubated with 100μL FITC-conjugated goat anti-mouse IgG1 for 30 min at 4°C with gentle shaking. Samples were analyzed on a FACSCalibur (Becton-Dickinson) using the software program CellQuest.
A total of 1 × 105 cells per well were cultured in flat-bottom 96-well plate in triplicates with the indicated concentration of purified antibody LaDR5 or TRAIL. 10μL per well MTT (10 mg/ml) was added and incubated for additional 4 hours at 37°C. Then 100μL 10% SDS containing 0.01 mol/L HCl was added and the plate was incubated for another 12 hours for light absorbance measurement at 570 nm with an ELISA reader.
For competing experiments, the concentration of LaDR5 or TRAIL was chosen with the OD value of about 50 % of saturated value, because it was sensitive to concentration change. Diluted DR5s were added at the same time to compete with membrane DR5 in binding LaDR5 or TRAIL, which would rescue cells from LaDR5-triggering apoptosis.
Jurkat cells were incubated with 10 μg/ml of LaDR5 for 30 min at 37°C. Cells were collected by centrifugation at 4°C for 5 min at 1,000 rpm, then after washing, cells were sprayed on glass slides with a Cytospin (Shandon, Astmoor, England), air dried and fixed with methanol for 1 min, stained with 10% Giemsa’s staining solution for 15 minutes, washed with distilled water, and finally air dried. The samples were examined in a light microscopy at 40× magnification.
Jurkat or Daudi cells (1 × 107 per sample) were treated with LaDR5 (10 mg/ml) for 1 hours at 37°C. Then cells were collected by centrifugation, lysed in IP buffer containing 20 mM Tris–HCl, 150 mM NaCl, 10 % glycerol, 2 mM EDTA, 0.57 mM PMSF, 1 % NP-40, pH8.0 and immunoprecipitated for 4 hours on ice. Then 15μL protein A beads (Sigma) per sample was added to the supernatant and after a hour’s washing, the beads were analyzed by western blot. Normal cell, isotype IgG treated cells and DR5-binding Antibody 366EC (with no apoptosis-inducing activity) were set as negative controls.
Gene cloning and sequencing of LaDR5
The VH and VL sequences of LaDR5 were determined by traditional method. In short, hybridoma cells were cultivated, collected and lyzed in TRIzol (Invitrogen). Then total RNA of LaDR5 were obtained using isopropyl alcohol-chloroform extraction. Then using reverse transcription and PCR with specific mouse antibody primers, the VH and VL region were subcloned into pGEM-Teasy vector (Promega) and sequenced.
Computer-guided molecular homology modeling
cDNAs encoding the variable domains of the light and heavy chains (VL and VH) of LaDR5 were derived from hybridoma cell by RT-PCR using consensus primers. The amino-acid residue sequences of the VL and VH of LaDR5 were compared with the primary sequences of all immunoglobulins deposited in the Protein Data Bank  using BLAST program (http://www.ncbi.nlm.nih.gov/BLAST/) . The CDR (Complementary Determinant Region) definition of LaDR5 variable domains was studied using Kabat method (http://immuno.bme.nwu.edu/) .
The best match for the VH domain of LaDR5 was the Fab-peptide complex structure (PDB code: 2hrp) , sharing 81% of sequence identity with the template, whereas the most homologous VL of LaDR5 was the crystal structure of an anti-HCG Fab (PDB code: 1sbs) , sharing 84% of sequence identity with the template. The structures were used as templates for computer-guided homology modeling of the 3-D theoretical structure of LaDR5 Fv fragment with HOMOLOGY program. The orientations of the VH and VL domains were generated by superimposition choosing the crystal structure of IgG1 Fab fragment (PDB code: 1igc)  as a scaffold template.
To optimize the steric clashes, the 3-D modeling structure of LaDR5 Fv fragment was subjected to energy minimization with 5000 steps of steepest descent followed by 10000 steps of conjugate gradient until the convergence criterion of 0.05 kCal/mol·Å was obtained under Charmm forcefield. Structural validation of LaDR5 Fv fragment was evaluated using Profile_3D program.
Based on the crystal structure of DR5 from PDB database (PDB code: 1d0g) , the theoretical structure of DR5 was optimized (5000 steps of steepest descent followed by 10000 steps of conjugate gradient) under Charmm forcefield. The 3-D complex structure of DR5 and LaDR5 was constructed using molecular docking method, where the CDR loops of LaDR5 were defined as the potential binding sites. DR5 and the potential binding sites were set to be flexible during the docking simulation and the modeling complex structure was energetically evaluated based on van der Waals and hydrogen bond interaction energy.
To avoid the conformation of the interaction domains trapped in a local potential energy minimum, residues at the base of the interaction domains were held fixed while the remainder of the interaction domains was subjected to simulated heating and molecular dynamics at elevated temperatures followed by slow cooling to a low energy conformation. The interaction domain residues were initially assigned a temperature of 300 K and slowly heated to 500 K in increments of 25 K, with 50 dynamics steps at each temperature using a time step of 1 fs. The structure was similarly heated to 1000, 2000, 3000 and 4000 K. At each temperature the interaction domains were subjected to a 100 ps dynamics run followed by slowing to 300 K, and two series of minimizations, first for 500 steps, then 3000 steps.
Based on the 3-D optimized complex structure of DR5 and LaDR5, the binding sites between DR5 and LaDR5 were predicted and a series of DR5 mutants were designed. The mutated sites in DR5M2 and DR5M3 were located at the coiled region of DR5, thus, the conformations of the mutants DR5M2 and DR5M3 remained the main orientation of the wild type of DR5 and did not change. The effect of DR5 did not affect.
Prokaryotic expression and purification of DR5WT and three mutants
Extracellular fragment of DR5 (DR5WT) and its three mutants (DR5M1, DR5M2 and DR5M3) were prepared as described . The expression plasmids were constructed using overlap PCR, enzymatic digestion and ligation. After sequencing, plasmids were transformed into E.coli BL21, respectively, and induced by 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) overnight at 20°C. Cells were collected by centrifugation, resuspended and lysed by sonication at 4°C. After centrifugation, supernatant was immediately loaded onto a Ni2+ nitrilotriacetic acid Sepharose affinity column. After being washed with 10 volumes of a binding buffer, the column was loaded with diluted imidazole (10 mM, 30 mM, 50 mM, 200 mM and 500 mM) in 20 mM PB, pH 8.0. The fusion proteins were collected and desalted using MILLPORE column (MWCO, 10000). The concentration of purified protein was calculated by ultraviolet spectrophotometer.
Grant support: This work was supported by National Sciences Fund (No. 30901381, No. 31070820), National key basic research development program (973 program, No. 2010CB833604) and National High Technology Research and Development Program (863 program, No. 2012AA02A302).
- Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science. 1997, 276: 111-113. 10.1126/science.276.5309.111.PubMedView ArticleGoogle Scholar
- Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997, 277: 815-818. 10.1126/science.277.5327.815.PubMedView ArticleGoogle Scholar
- Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997, 277: 818-821. 10.1126/science.277.5327.818.PubMedView ArticleGoogle Scholar
- Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997, 16: 5386-5397. 10.1093/emboj/16.17.5386.PubMedPubMed CentralView ArticleGoogle Scholar
- Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A: Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000, 12: 611-620. 10.1016/S1074-7613(00)80212-5.PubMedView ArticleGoogle Scholar
- Thomas LR, Henson A, Reed JC, Salsbury FR, Thorburn A: Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD. J Biol Chem. 2004, 279: 32780-32785. 10.1074/jbc.M401680200.PubMedView ArticleGoogle Scholar
- Thomas LR, Johnson RL, Reed JC, Thorburn A: The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J Biol Chem. 2004, 279: 52479-52486. 10.1074/jbc.M409578200.PubMedView ArticleGoogle Scholar
- Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A: Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2005, 280: 40599-40608. 10.1074/jbc.M509560200.PubMedView ArticleGoogle Scholar
- Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002, 2: 420-430. 10.1038/nrc821.PubMedView ArticleGoogle Scholar
- Thorburn A: Death receptor-induced cell killing. Cell Signal. 2004, 16: 139-144. 10.1016/j.cellsig.2003.08.007.PubMedView ArticleGoogle Scholar
- Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA: Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med. 1997, 186: 1165-1170. 10.1084/jem.186.7.1165.PubMedPubMed CentralView ArticleGoogle Scholar
- Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 1997, 7: 1003-1006. 10.1016/S0960-9822(06)00422-2.PubMedView ArticleGoogle Scholar
- Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG: The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 1997, 7: 813-820. 10.1016/S1074-7613(00)80399-4.PubMedView ArticleGoogle Scholar
- Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N: J Tschopp Characterization of two receptors for TRAIL. FEBS Lett. 1997, 416: 329-334. 10.1016/S0014-5793(97)01231-3.PubMedView ArticleGoogle Scholar
- Pan G, Ni J, Yu G, Wei YF, Dixit VM: TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 1998, 424: 41-45. 10.1016/S0014-5793(98)00135-5.PubMedView ArticleGoogle Scholar
- Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006, 26: 7046-7055. 10.1128/MCB.00520-06.PubMedPubMed CentralView ArticleGoogle Scholar
- Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK: Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA. 2005, 102: 18099-18104. 10.1073/pnas.0507329102.PubMedPubMed CentralView ArticleGoogle Scholar
- Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA: Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem. 2000, 275: 23319-23325. 10.1074/jbc.M910438199.PubMedView ArticleGoogle Scholar
- Cha SS, Sung BJ, Kim YA, Song YL, Kim HJ, Kim S, Lee MS, Oh BH: Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem. 2000, 275: 31171-31177.PubMedView ArticleGoogle Scholar
- Griffith TS, Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998, 10: 559-563. 10.1016/S0952-7915(98)80224-0.PubMedView ArticleGoogle Scholar
- Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999, 104: 155-162. 10.1172/JCI6926.PubMedPubMed CentralView ArticleGoogle Scholar
- Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999, 5: 157-163. 10.1038/5517.PubMedView ArticleGoogle Scholar
- Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, Ashkenazi A, Kim KJ: Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol. 2001, 166: 4891-4898.PubMedView ArticleGoogle Scholar
- Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP: Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 2001, 7: 954-960. 10.1038/91000.PubMedView ArticleGoogle Scholar
- LeBlanc HN, Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003, 10: 66-75. 10.1038/sj.cdd.4401187.PubMedView ArticleGoogle Scholar
- Wang S, El-Deiry WS: TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003, 22: 8628-8633. 10.1038/sj.onc.1207232.PubMedView ArticleGoogle Scholar
- Bouralexis S, Findlay DM, Evdokiou A: Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis. 2005, 10: 35-51. 10.1007/s10495-005-6060-0.PubMedView ArticleGoogle Scholar
- Kelley SK, Ashkenazi A: Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol. 2004, 4: 333-339. 10.1016/j.coph.2004.02.006.PubMedView ArticleGoogle Scholar
- Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, Carpenter M, LoBuglio AF: Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res. 2003, 9: 3731-3741.PubMedGoogle Scholar
- Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000, 6: 564-567. 10.1038/75045.PubMedView ArticleGoogle Scholar
- Fox NL, Humphreys R, Luster TA, Klein J, Gallant G: Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy. Expert Opin Biol Ther. 2010, 10: 1-18. 10.1517/14712590903319656.PubMedView ArticleGoogle Scholar
- Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V, Diamond P, Zannettino AC, Findlay DM, Evdokiou A: Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Mol Cancer Ther. 2009, 8: 2969-2980. 10.1158/1535-7163.MCT-09-0745.PubMedView ArticleGoogle Scholar
- Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, Lawrence D, Zheng Z, Koeppen H, Stern H: Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res. 2008, 14: 7733-7740. 10.1158/1078-0432.CCR-08-0670.PubMedView ArticleGoogle Scholar
- Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S, Fujiwara K: A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol. 2008, 19: 1060-1067. 10.1093/annonc/mdn015.PubMedView ArticleGoogle Scholar
- Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M: Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ. 2008, 15: 751-761. 10.1038/sj.cdd.4402306.PubMedView ArticleGoogle Scholar
- Du YW, Liu GC, Wang J, Zhao YP, Li SL, Chen JG, Jiang Q, Cai J, Ma YF: Caspase-dependent molecular mechanisms of anti-human DR5 monoclonal antibody mDRA-6 inducing apoptosis of human leukemia Jurkat cells. Ai Zheng. 2009, 28: 112-116.PubMedGoogle Scholar
- Zuker M, Somorjai RL: The alignment of protein structures in three dimensions. Bull Math Biol. 1989, 51: 55-78.PubMedView ArticleGoogle Scholar
- Russo M, Mupo A, Spagnuolo C, Russo GL: Exploring death receptor pathways as selective targets in cancer therapy. Biochem Pharmacol. 2010, 80: 674-682. 10.1016/j.bcp.2010.03.011.PubMedView ArticleGoogle Scholar
- Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME: Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods. 1985, 77: 305-319. 10.1016/0022-1759(85)90044-4.PubMedView ArticleGoogle Scholar
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000, 28: 235-242. 10.1093/nar/28.1.235.PubMedPubMed CentralView ArticleGoogle Scholar
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25: 3389-3402. 10.1093/nar/25.17.3389.PubMedPubMed CentralView ArticleGoogle Scholar
- Kabat EA, Wu TT: Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol. 1991, 147: 1709-1719.PubMedGoogle Scholar
- Lescar J, Stouracova R, Riottot MM, Chitarra V, Brynda J, Fabry M, Horejsi M, Sedlacek J, Bentley GA: Three-dimensional structure of an Fab-peptide complex: structural basis of HIV-1 protease inhibition by a monoclonal antibody. J Mol Biol. 1997, 267: 1207-1222. 10.1006/jmbi.1997.0950.PubMedView ArticleGoogle Scholar
- Fotinou C, Beauchamp J, Emsley P, deHaan A, Schielen WJ, Bos E, Isaacs NW: Structure of an Fab fragment against a C-terminal peptide of hCG at 2.0 A resolution. J Biol Chem. 1998, 273: 22515-22518. 10.1074/jbc.273.35.22515.PubMedView ArticleGoogle Scholar
- Derrick JP, Wigley DB: The third IgG-binding domain from streptococcal protein G. An analysis by X-ray crystallography of the structure alone and in a complex with Fab. J Mol Biol. 1994, 243: 906-918. 10.1006/jmbi.1994.1691.PubMedView ArticleGoogle Scholar
- Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A, de Vos AM: Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell. 1999, 4: 563-571. 10.1016/S1097-2765(00)80207-5.PubMedView ArticleGoogle Scholar
- Chen JG, Wang YG, Zhao KP, Gu X, Li Y, Ma YF, Shen BF: Gene expression and primary functional characterization of human DR5 extracellular fragment. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007, 23: 791-793.PubMedGoogle Scholar